Target Name: CD101
NCBI ID: G9398
Review Report on CD101 Target / Biomarker Content of Review Report on CD101 Target / Biomarker
CD101
Other Name(s): leukocyte surface protein | IgSF2 | IGSF2_HUMAN | IGSF2 | Leukocyte surface protein | Glu-Trp-Ile EWI motif-containing protein 101 | V7 | Immunoglobulin superfamily member 2 | glu-Trp-Ile EWI motif-containing protein 101 | cell surface glycoprotein V7 | Cell surface glycoprotein V7 | Immunoglobulin superfamily, member 2 | OTTHUMP00000013817 | EWI101 | EWI-101 | CD101 molecule | CD101 variant 1 | CD101 molecule, transcript variant 1 | Immunoglobulin superfamily member 2 (isoform 1)

CD101: A Promising Drug Target and Biomarker for Leukocyte Surface Protein

Leukocyte surface protein (LSP) is a unique transmembrane protein that plays a crucial role in the functions of leukocytes, including their recruitment, activation, and proliferation. CD101, a type of LSP, is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

CD101: A protein that regulates leukocyte functions

CD101 is a 12-kDa protein that is expressed in a variety of tissues, including blood, bone marrow, and brain. It is highly expressed in human primary leukocytes, including neutrophils and monocytes, and is involved in the regulation of leukocyte functions, including:

1. Recruitment and activation of leukocytes: CD101 is known to play a critical role in the recruitment of neutrophils to sites of infection or injury. It interacts with integrins on the surface of these cells and may influence the decision to activate these cells for immune defense.
2. Granule exocytosis and phagocytosis: CD101 is involved in the exocytosis of granules, which are packets containing enzymes and other bioactive molecules, from the mitochondria to the cytoplasm. This process is essential for the activation and function of neutrophils.
3. Adhesion and migration: CD101 is critical for the adhesion and migration of neutrophils to sites of infection or injury. It may influence the interactions between neutrophils and other immune cells, as well as the regulation of their extravasation through endothelial cells.
4. Proliferation and apoptosis: CD101 is involved in the regulation of leukocyte proliferation and apoptosis. It has been shown to play a role in the regulation of granulocyte maturation and differentiation, as well as the detoxification of environmental toxins.

CD101 as a potential drug target

The potential drug targeting of CD101 is based on its unique role in the regulation of leukocyte functions and its involvement in various diseases. Several studies have suggested that CD101 may be a promising target for drugs that target signaling pathways involved in cell proliferation, differentiation, and inflammation.

CD101 has been shown to play a role in the regulation of several signaling pathways that are involved in cancer progression, including the TGF-β pathway, which is involved in cell proliferation and survival, and the NF-kappa-B pathway, which is involved in inflammation and immune responses.

CD101 has also been shown to interact with several protein molecules that are involved in the regulation of signaling pathways that are involved in neurodegenerative diseases, including the Tau protein, which is involved in the regulation of neurotransmitter release and the N-methyl-D-aspartate (NMDA) receptor, which is involved in neurotransmitter release and pain signaling.

CD101 as a biomarker

CD101 has also been suggested as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The expression of CD101 has been shown to be elevated in a variety of tissues and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders.

CD101 has also been shown to be involved in the regulation of several biological processes that are involved in the development and progression of these diseases, including the regulation of cell proliferation, apoptosis, and angiogenesis.

Conclusion

CD101 is a unique and highly expressed protein that is involved in the regulation of leukocyte functions and the development and progression of various diseases. Its potential as a drug target and biomarker makes it an attractive target for further research and development. Further studies are needed to fully understand the role of CD101 in

Protein Name: CD101 Molecule

Functions: Plays a role as inhibitor of T-cells proliferation induced by CD3. Inhibits expression of IL2RA on activated T-cells and secretion of IL2. Inhibits tyrosine kinases that are required for IL2 production and cellular proliferation. Inhibits phospholipase C-gamma-1/PLCG1 phosphorylation and subsequent CD3-induced changes in intracellular free calcium. Prevents nuclear translocation of nuclear factor of activated T-cell to the nucleus. Plays a role in the inhibition of T-cell proliferation via IL10 secretion by cutaneous dendritic cells. May be a marker of CD4(+) CD56(+) leukemic tumor cells

The "CD101 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD101 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA